APA (7th ed.) Citation

JE, M., MS, F., W, R., JP, L., A, D., WG, L., . . . D, B. (2024). Exeporfinium chloride (XF-73) nasal gel significantly reduces Staphylococcus aureus nasal carriage in cardiac surgery patients throughout surgery and the early recovery period: Results from a randomized placebo-controlled Phase 2 study. Infection control and hospital epidemiology, 45(11), 1355. https://doi.org/10.1017/ice.2024.122

Chicago Style (17th ed.) Citation

JE, Mangino, Firstenberg MS, Rhys-Williams W, Lees JP, Dane A, Love WG, Gonzalez Moreno J, Martina Y, and Barker D. "Exeporfinium Chloride (XF-73) Nasal Gel Significantly Reduces Staphylococcus Aureus Nasal Carriage in Cardiac Surgery Patients Throughout Surgery and the Early Recovery Period: Results from a Randomized Placebo-controlled Phase 2 Study." Infection Control and Hospital Epidemiology 45, no. 11 (2024): 1355. https://doi.org/10.1017/ice.2024.122.

MLA (9th ed.) Citation

JE, Mangino, et al. "Exeporfinium Chloride (XF-73) Nasal Gel Significantly Reduces Staphylococcus Aureus Nasal Carriage in Cardiac Surgery Patients Throughout Surgery and the Early Recovery Period: Results from a Randomized Placebo-controlled Phase 2 Study." Infection Control and Hospital Epidemiology, vol. 45, no. 11, 2024, p. 1355, https://doi.org/10.1017/ice.2024.122.